Experience

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including…

Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 4,000,000 shares of common stock of PTC…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $800 million public offering by BeiGene, Ltd. of American depositary shares. The ADSs are…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S reopening by Hologic, Inc. of $600 million aggregate principal amount of its 4…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $402.5 million principal amount of its 1.375% convertible senior notes due…

Davis Polk advised the representative of the initial purchasers on a Rule 144A/Regulation S offering by Hologic, Inc. of $350 million aggregate principal amount of its 4.375% senior…

Davis Polk advised the joint book-running managers and representatives of the underwriters on the $201 million public offering by BeiGene, Ltd. of American Depositary Shares. The ADSs…

Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…

Davis Polk advised the sole book-running manager in connection with Galapagos NV’s offering of 4,312,500 ordinary shares in the form of American depositary shares, which includes the full…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million aggregate principal amount of its 2.00% senior convertible notes…